Standard

Effects of Liraglutide on Myocardial Function After Cardiac Surgery : A Secondary Analysis of the Randomised Controlled GLOBE Trial. / Hulst, Abraham H.; Visscher, Maarten J.; Cherpanath, Thomas G.V. et al.

In: Journal of clinical medicine, Vol. 9, No. 3, 673, 02.03.2020.

Research output: Contribution to journalArticleAcademicpeer-review

Harvard

APA

Vancouver

Hulst AH, Visscher MJ, Cherpanath TGV, van de Wouw L, Godfried MB, Thiel B et al. Effects of Liraglutide on Myocardial Function After Cardiac Surgery: A Secondary Analysis of the Randomised Controlled GLOBE Trial. Journal of clinical medicine. 2020 Mar 2;9(3):673. doi: 10.3390/jcm9030673, 10.3390/jcm9030673

Author

BibTeX

@article{b0122475d1bd40c79f54685212c555f2,
title = "Effects of Liraglutide on Myocardial Function After Cardiac Surgery: A Secondary Analysis of the Randomised Controlled GLOBE Trial",
abstract = "Introduction: Previous studies demonstrated the cardioprotective properties of glucagon-like peptide-1 receptor agonists in patients with diabetes or cardiac disease. We investigated whether preoperative subcutaneous liraglutide improves myocardial function after cardiac surgery. Methods: We performed a pre-planned secondary analysis of adult patients undergoing cardiac surgery included in the GLOBE trial. Patients were randomised to receive 0.6 mg subcutaneous liraglutide on the evening before surgery and 1.2 mg after induction of anaesthesia, or matching placebo. Perioperative echocardiographic assessments, haemodynamic parameters, doses of vasoactive inotropic support and postoperative measurements of troponin, Creatine Kinase-MB, creatinine and lactate were compared between groups. Results: The study population consisted of the entire intention-to-treat cohort of the GLOBE trial. In this study, 129 patients received liraglutide and 132 patients placebo. Baseline characteristics were comparable between groups. Postoperatively, 170 (65%) patients underwent echocardiography. In the liraglutide group, more patients had a normal left ventricular systolic function (68%, 59 patients) compared to placebo (53%, 44 patients), difference = 15%, 95%CI = 0–30, p = 0.049. Assessment of the right ventricle revealed no difference in function. Conclusions: Patients receiving short-term preoperative liraglutide treatment better maintained normal myocardial function after cardiac surgery. This study warrants further evaluation of the potential beneficial effects of GLP-1 receptor agonists in cardiac surgery patients.",
keywords = "Cardiac function, CK-MB, Echocardiography, Left ventricular function, Liraglutide, Placebo, Randomised controlled trial, Troponin",
author = "Hulst, {Abraham H.} and Visscher, {Maarten J.} and Cherpanath, {Thomas G.V.} and {van de Wouw}, Lieke and Godfried, {Marc B.} and Bram Thiel and Gerritse, {Bastiaan M.} and Scohy, {Thierry V.} and Bouwman, {R. Arthur} and Willemsen, {Mark G.A.} and Hollmann, {Markus W.} and Devries, {J. Hans} and Benedikt Preckel and Jeroen Hermanides",
note = "Publisher Copyright: {\textcopyright} 2020 by the authors. Licensee MDPI, Basel, Switzerland. Copyright: Copyright 2021 Elsevier B.V., All rights reserved.",
year = "2020",
month = mar,
day = "2",
doi = "10.3390/jcm9030673",
language = "English",
volume = "9",
journal = "Journal of clinical medicine",
issn = "2077-0383",
publisher = "Multidisciplinary Digital Publishing Institute (MDPI)",
number = "3",

}

RIS

TY - JOUR

T1 - Effects of Liraglutide on Myocardial Function After Cardiac Surgery

T2 - A Secondary Analysis of the Randomised Controlled GLOBE Trial

AU - Hulst, Abraham H.

AU - Visscher, Maarten J.

AU - Cherpanath, Thomas G.V.

AU - van de Wouw, Lieke

AU - Godfried, Marc B.

AU - Thiel, Bram

AU - Gerritse, Bastiaan M.

AU - Scohy, Thierry V.

AU - Bouwman, R. Arthur

AU - Willemsen, Mark G.A.

AU - Hollmann, Markus W.

AU - Devries, J. Hans

AU - Preckel, Benedikt

AU - Hermanides, Jeroen

N1 - Publisher Copyright: © 2020 by the authors. Licensee MDPI, Basel, Switzerland. Copyright: Copyright 2021 Elsevier B.V., All rights reserved.

PY - 2020/3/2

Y1 - 2020/3/2

N2 - Introduction: Previous studies demonstrated the cardioprotective properties of glucagon-like peptide-1 receptor agonists in patients with diabetes or cardiac disease. We investigated whether preoperative subcutaneous liraglutide improves myocardial function after cardiac surgery. Methods: We performed a pre-planned secondary analysis of adult patients undergoing cardiac surgery included in the GLOBE trial. Patients were randomised to receive 0.6 mg subcutaneous liraglutide on the evening before surgery and 1.2 mg after induction of anaesthesia, or matching placebo. Perioperative echocardiographic assessments, haemodynamic parameters, doses of vasoactive inotropic support and postoperative measurements of troponin, Creatine Kinase-MB, creatinine and lactate were compared between groups. Results: The study population consisted of the entire intention-to-treat cohort of the GLOBE trial. In this study, 129 patients received liraglutide and 132 patients placebo. Baseline characteristics were comparable between groups. Postoperatively, 170 (65%) patients underwent echocardiography. In the liraglutide group, more patients had a normal left ventricular systolic function (68%, 59 patients) compared to placebo (53%, 44 patients), difference = 15%, 95%CI = 0–30, p = 0.049. Assessment of the right ventricle revealed no difference in function. Conclusions: Patients receiving short-term preoperative liraglutide treatment better maintained normal myocardial function after cardiac surgery. This study warrants further evaluation of the potential beneficial effects of GLP-1 receptor agonists in cardiac surgery patients.

AB - Introduction: Previous studies demonstrated the cardioprotective properties of glucagon-like peptide-1 receptor agonists in patients with diabetes or cardiac disease. We investigated whether preoperative subcutaneous liraglutide improves myocardial function after cardiac surgery. Methods: We performed a pre-planned secondary analysis of adult patients undergoing cardiac surgery included in the GLOBE trial. Patients were randomised to receive 0.6 mg subcutaneous liraglutide on the evening before surgery and 1.2 mg after induction of anaesthesia, or matching placebo. Perioperative echocardiographic assessments, haemodynamic parameters, doses of vasoactive inotropic support and postoperative measurements of troponin, Creatine Kinase-MB, creatinine and lactate were compared between groups. Results: The study population consisted of the entire intention-to-treat cohort of the GLOBE trial. In this study, 129 patients received liraglutide and 132 patients placebo. Baseline characteristics were comparable between groups. Postoperatively, 170 (65%) patients underwent echocardiography. In the liraglutide group, more patients had a normal left ventricular systolic function (68%, 59 patients) compared to placebo (53%, 44 patients), difference = 15%, 95%CI = 0–30, p = 0.049. Assessment of the right ventricle revealed no difference in function. Conclusions: Patients receiving short-term preoperative liraglutide treatment better maintained normal myocardial function after cardiac surgery. This study warrants further evaluation of the potential beneficial effects of GLP-1 receptor agonists in cardiac surgery patients.

KW - Cardiac function

KW - CK-MB

KW - Echocardiography

KW - Left ventricular function

KW - Liraglutide

KW - Placebo

KW - Randomised controlled trial

KW - Troponin

UR - http://www.scopus.com/inward/record.url?scp=85097898779&partnerID=8YFLogxK

U2 - 10.3390/jcm9030673

DO - 10.3390/jcm9030673

M3 - Article

C2 - 32131527

VL - 9

JO - Journal of clinical medicine

JF - Journal of clinical medicine

SN - 2077-0383

IS - 3

M1 - 673

ER -

ID: 15530112